26 citations
,
October 2018 in “Clinical & Translational Oncology” This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.
149 citations
,
January 2015 in “Journal of the American Academy of Dermatology” This review discusses skin-related adverse effects from targeted cancer therapies in dermatology but does not provide new clinical results, emphasizing the essential role of dermatologists in managing these toxicities.
October 2023 in “Frontiers in medicine” Targeted immunotherapy could be a promising new treatment for hair regrowth.
2 citations
,
November 2024 in “JAAD reviews.” This review reported that certain systemic drugs, including antiepileptics and anticancer drugs, can lead to changes in hair pigmentation, such as hypopigmentation or hyperpigmentation, with varied prevalence and clinical characteristics.